Moleculin Biotech (NASDAQ: MBRX) Reports 2025 Financials and Confirms MIRACLE Trial Progress
Expert Analysis Moleculin Biotech, Inc. (NASDAQ: MBRX) continues to make significant strides in the treatment of refractory and relapsed acute myeloid leukemia (AML) through its innovative therapy, Annamycin, combined with cytarabine. The Company’s forthcoming interim data from the MIRACLE pivotal trial is a crucial milestone that could validate its therapeutic approach and impact treatment paradigms for AML patients with limited options. Investors and industry experts are closely monitoring Moleculin Biotech…
